Trial Profile

A Phase II, Open-Label, Ascending High-Dose, Add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Perampanel (Primary) ; Antiepileptic drugs; Carbamazepine; Clobazam; Clonazepam; Gabapentin; Lamotrigine; Phenobarbital; Phenytoin; Topiramate; Valproate; Zonisamide
Indications Generalised seizures; Partial epilepsies
Focus Adverse reactions
Sponsors Eisai Co Ltd

Most Recent Events

30 Nov 2016 According to an Eisai media release, the company will present results of this study at the 70th American Epilepsy Society (AES) Annual Meeting.
19 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
15 Sep 2009 Actual initiation date changed from Feb 2009 to Mar 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com